Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia

Gabriel Tremblay,1 Mike Dolph,1 Menaka Bhor,2 Qayyim Said,2 Anuja Roy,2 Brian Elliott,3 Andrew Briggs4 1Health Economics, Purple Squirrel Economics, New York, NY, USA; 2Health Economics and Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Hematology, No...

Full description

Bibliographic Details
Main Authors: Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
chronic immune thrombocytopenia
eltrombopag
romiplostim
cost-consequence
USA
Online Access:https://www.dovepress.com/cost-consequence-model-comparing-eltrombopag-and-romiplostim-in-pediat-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-consequence-model-comparing-eltrombopag-and-romiplostim-in-pediat-peer-reviewed-article-CEOR

Similar Items